News
FDA Approves Emcitate as First Treatment for MCT8 Deficiency
Egetis’ Emcitate is the first and only approved treatment for MCT8 deficiency, with marketing authorisations in the EU and the US.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Egetis’ Emcitate is the first and only approved treatment for MCT8 deficiency, with marketing authorisations in the EU and the US.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
